IPA - The HUB of Biotherapeutic Intelligence™

IPA - The HUB of Biotherapeutic Intelligence™

#IPA #ImmunoPreciseAntibodies #JenniferBath

Hi, and welcome to the show!

On today’s show I have the pleasure of welcoming IPA CEO Dr. Jennifer Bath to talk about IPA, what it does, it’s core mission, what the future holds for antibody development, and to explore the value that IPA brings to the marketplace.

Jennifer Bath is the CEO and President of IPA. She obtained a Ph.D. in Cellular and Molecular Biology, specializing in immunology and biochemistry with a focus on discovering and validating biologics for the prevention and treatment of neglected tropical diseases.

Jennifer held a tenured position as an Associate Professor of Cellular and Molecular Biology, while concurrently serving as the Founder and Executive Director of the Concordia Global Vaccine Institute. She also served many years as a strategic growth and business operations advisor for global pharma, biotech, and government.

Jennifer has held executive roles in both biotechnology and contract research organizations, with her most recent post on the executive team at Aldevron, LLC. There, she headed the global sales and client relations teams, and dened business strategies by applying knowledge based on the science, technology, and market. In addition, she served as a key technical specialist, converting challenges for pharmaceutical and biotechnology clients into operational initiatives.

IPA TICKER: NASDAQ: IPA

To learn more about IPA and the topics discussed, or to contact Dr. Bath directly, click the link below.

https://myfuturebusiness.com/ipa